Pharvaris N.V. Ordinary Shares PHVS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T03:06:58.026Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:00.253339135Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T03:06:57.662234+00:00
Pharvaris N.V. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 25.44 | 321.7% | 32.7% | |||
| 25Δ | 28.29 | 253.9% | 24.4% | |||
| 30Δ | 45.32 | 255.0% | 39.0% | 30.38 | 206.7% | 18.3% |
| 35Δ | 42.22 | 237.7% | 30.7% | 31.87 | 175.8% | 14.2% |
| 40Δ | 38.65 | 191.9% | 20.3% | 32.98 | 151.8% | 11.2% |
| 45Δ | 36.57 | 160.6% | 14.3% | 33.81 | 132.8% | 8.8% |
| 50Δ | 35.00 | 135.3% | 9.8% | 34.64 | 113.8% | 6.5% |
| 55Δ | 34.30 | 120.3% | 7.9% | 35.28 | 101.9% | 5.0% |
| 60Δ | 33.60 | 105.4% | 6.0% | 35.78 | 95.4% | 4.2% |
| 65Δ | 32.90 | 90.5% | 4.1% | 36.29 | 88.8% | 3.4% |
| 70Δ | 32.12 | 84.7% | 2.8% | 36.79 | 82.3% | 2.5% |
| 75Δ | 31.24 | 91.1% | 2.4% | 37.29 | 75.7% | 1.7% |
| 80Δ | 30.35 | 97.5% | 1.9% | 38.46 | 79.9% | 1.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.44
- IV
- 321.7%
- B/E move
- 32.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 28.29
- IV
- 253.9%
- B/E move
- 24.4%
30Δ
- Pseudo strike
- 45.32
- IV
- 255.0%
- B/E move
- 39.0%
- Pseudo strike
- 30.38
- IV
- 206.7%
- B/E move
- 18.3%
35Δ
- Pseudo strike
- 42.22
- IV
- 237.7%
- B/E move
- 30.7%
- Pseudo strike
- 31.87
- IV
- 175.8%
- B/E move
- 14.2%
40Δ
- Pseudo strike
- 38.65
- IV
- 191.9%
- B/E move
- 20.3%
- Pseudo strike
- 32.98
- IV
- 151.8%
- B/E move
- 11.2%
45Δ
- Pseudo strike
- 36.57
- IV
- 160.6%
- B/E move
- 14.3%
- Pseudo strike
- 33.81
- IV
- 132.8%
- B/E move
- 8.8%
50Δ
- Pseudo strike
- 35.00
- IV
- 135.3%
- B/E move
- 9.8%
- Pseudo strike
- 34.64
- IV
- 113.8%
- B/E move
- 6.5%
55Δ
- Pseudo strike
- 34.30
- IV
- 120.3%
- B/E move
- 7.9%
- Pseudo strike
- 35.28
- IV
- 101.9%
- B/E move
- 5.0%
60Δ
- Pseudo strike
- 33.60
- IV
- 105.4%
- B/E move
- 6.0%
- Pseudo strike
- 35.78
- IV
- 95.4%
- B/E move
- 4.2%
65Δ
- Pseudo strike
- 32.90
- IV
- 90.5%
- B/E move
- 4.1%
- Pseudo strike
- 36.29
- IV
- 88.8%
- B/E move
- 3.4%
70Δ
- Pseudo strike
- 32.12
- IV
- 84.7%
- B/E move
- 2.8%
- Pseudo strike
- 36.79
- IV
- 82.3%
- B/E move
- 2.5%
75Δ
- Pseudo strike
- 31.24
- IV
- 91.1%
- B/E move
- 2.4%
- Pseudo strike
- 37.29
- IV
- 75.7%
- B/E move
- 1.7%
80Δ
- Pseudo strike
- 30.35
- IV
- 97.5%
- B/E move
- 1.9%
- Pseudo strike
- 38.46
- IV
- 79.9%
- B/E move
- 1.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 64.79% | |
| 61.03% | |
| 67.33% | |
| 68.49% | |
| 67.40% | |
| 70.28% | |
| 71.96% | |
| 71.86% | |
| 64.31% | |
| 70.52% |
Biotechnology
PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary…
More →PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The…
More →PRLD
Description unavailable
More →PRME
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA…
More →PROK
ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.
More →PRQR
Description unavailable
More →